News | January 30, 2026
Biocon Biologics gets credit boost from S&P, outlook stable
The rating on senior secured notes issued by Biocon Biologics Global PLC was also upgraded to ‘BB+.’
The rating on senior secured notes issued by Biocon Biologics Global PLC was also upgraded to ‘BB+.’
The company has posted net profit of Rs. 4,064.9 crore for the 9 months period ended December 31, 2025
The proceeds from the ?IP will be primarily utilized to meet the cash consideration payable to Mylan Inc. (Viatris) for buying out its shareholding in Biocon Biologics Limited
CuraTeQ Biologics and BioFactura USA to terminate agreement mutually
Production at Biocon Biologics’ own facilities is scheduled to begin once technology transfers and regulatory approvals are finalized
This recognition demonstrate excellence in intellectual property (IP) value creation.
All pending litigation between Biocon Biologics, Regeneron, and Bayer will be dismissed
Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million
Valorum will advance the commercialization and distribution of Armlupeg in the United States
Armlupeg is indicated for decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs
Subscribe To Our Newsletter & Stay Updated
